Skip to main content
. 2015 Apr 1;8(4):3871–3881.

Figure 2.

Figure 2

Effects of SOX9 expression and Sorafenib/Sunitinib on the renal carcinoma cells. A: si-SOX9-1significantly decreased SOX9 mRNA and protein expression detected by RT-PCR, qPCR, WB (with β-actin and GAPDH as internal control, mean ± SD of three independent experiments, P < 0.05). B: Down-regulation of SOX9 couldreduce the viability of renal carcinoma cells 786-O and A498. C: left: the effect of Sorafenib (5 uM, 10 uM, 15 uM and 20 uM)/Sunitinib (1 uM, 2 uM, 3 uM and 4 uM) on renal carcinoma cell lines for 48h. middle: the effect of Sorafenib (5 uM, 10 uM and 15 uM) /Sunitinib (1 uM, 2 uM and 3 uM) on 786-O cells. Right: Co-treatment of si-SOX9 and Sorafenib (10 uM and 15 uM) /Sunitinib (2 uM and 3 uM) can significantly inhibit the growth of 786-O cells D: Co-treatment of si-SOX9-1and Sorafenib (10 uM and 15 uM) /Sunitinib (2 uM and 3 uM) could significantly induce apoptosis of 786-O cells measured by Flow Cytometry.